We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.22 | -0.15% | 149.70 | 149.89 | 147.82 | 149.89 | 6,532,721 | 00:38:06 |
From Nov 2023 to May 2024
By Colin Kellaher
Integra LifeSciences Holdings has agreed to buy ear, nose and throat (ENT) technology company Acclarent from a unit of Johnson & Johnson for $275 million in cash.
Integra on Wednesday said the deal, which expands its portfolio of ENT products and technologies, also includes an additional $5 million based on the achievement of certain regulatory milestones.
Princeton, N.J., medical-technology company Integra said Acclarent generated about $110 million in revenue in 2022.
Integra, which has forecast revenue of $1.54 billion to $1.55 billion for 2023, said it expects to complete the acquisition by the second quarter of 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 13, 2023 06:48 ET (11:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
